Who Owns Xencor Company?

Xencor Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Owns Xencor?

Understanding the ownership structure of a company like Xencor, a biopharmaceutical innovator, is crucial for investors and stakeholders alike. From its inception in 1997 to its current market capitalization of approximately $1.64 billion (as of June 2024), Xencor's journey is a testament to the impact of its ownership dynamics. The evolution of its ownership, especially after its IPO, has shaped its strategic direction and influenced its market position. This deep dive will uncover the key players behind Xencor SWOT Analysis and their influence.

This exploration of "Who owns Xencor" will examine the shifts in Xencor ownership, from the founders' initial stakes to the influence of major shareholders and institutional investors. Analyzing the Xencor company ownership structure provides valuable insights into the company's strategic decisions and potential for growth. Knowing the Xencor investors and Xencor executives behind the scenes is key to assessing the company's future prospects, including Xencor stock performance.

The Xencor company was established in 1997. The founders, Bassil Dahiyat, Ph.D., and Stephen Mayo, Ph.D., laid the groundwork for its scientific and technological advancements. The initial ownership structure reflected their pivotal roles in the company's early development.

Early funding rounds likely included angel investors, venture capital firms, and potentially contributions from friends and family. These early investors received equity in exchange for their financial support, which shaped the initial capital structure. The vision of the founders, focused on protein engineering to develop new therapeutics, influenced the distribution of control and the company's strategic direction.

Agreements regarding equity, such as buy-sell clauses, were crucial in defining the rights and obligations of the founding shareholders and early investors. These agreements helped to establish the framework for future ownership changes and the company's growth trajectory. Understanding the initial ownership structure provides insights into the company's early strategic decisions and its financial landscape.

Key Aspects of Early Ownership

The initial ownership of the Xencor company was primarily held by its founders, Bassil Dahiyat and Stephen Mayo. Early investors, including angel investors and venture capital firms, also played a significant role in shaping the ownership structure. The founders' vision for protein engineering influenced the company's strategic direction and control.

• Founders' Stakes: Founders typically held significant initial stakes, often subject to vesting schedules.
• Early Investors: Angel investors and venture capital firms provided early funding, acquiring equity.
• Equity Agreements: Buy-sell clauses and other agreements defined shareholder rights and obligations.
• Strategic Direction: The founders' vision guided the company's early strategic decisions.

Xencor SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership structure of the Xencor company has transformed significantly since its inception. A pivotal moment was the initial public offering (IPO) on December 11, 2013. The company began trading on the NASDAQ Global Select Market under the ticker 'XNCR'. This transition from a private to a public entity broadened its ownership base, including a diverse group of institutional and individual investors. The IPO marked a key step in Xencor's evolution, changing how the company was funded and governed.

As of the first quarter of 2024, institutional investors hold a significant portion of Xencor's shares. Approximately 98.79% of the company's stock is owned by institutions. This high percentage indicates strong confidence from large investment firms in Xencor's potential. Major shareholders play a critical role in the company's direction, influencing decisions through proxy voting and direct communication with management. This impacts strategic choices related to drug development and financial management.

Other significant institutional holders include ARK Investment Management LLC, Orbimed Advisors LLC, and Geode Capital Management, LLC. The involvement of these major stakeholders reflects the typical pattern for publicly traded biopharmaceutical companies. These firms seek exposure to the growth potential of innovative drug development. Understanding the dynamics of Xencor ownership is crucial for investors. For more insights into the company's strategic approach, consider exploring the Target Market of Xencor.

Key Takeaways on Xencor Ownership

The majority of Xencor stock is held by institutional investors. This ownership structure is common in the biotech industry, reflecting confidence from major financial players.

• Institutional investors hold approximately 98.79% of Xencor's shares.
• Vanguard and BlackRock are among the major Xencor investors.
• Xencor executives and board members also hold shares.
• The IPO in 2013 was a major turning point for Xencor company ownership.

Xencor PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors at Xencor, as of early 2025, oversees the company's direction, balancing the interests of various stakeholders. The board typically includes independent directors, industry experts, and potentially individuals connected to major shareholders or the founding team. For instance, Bassil Dahiyat, a co-founder, serves as President and CEO and is on the Board, demonstrating the continued influence of the founding vision. Understanding the composition of the board is crucial for investors interested in Xencor ownership and its strategic direction.

The board's decisions significantly impact Xencor investors, particularly institutional holders who collectively hold a substantial portion of the company's voting power. The board's oversight is essential, especially given the presence of large institutional investors. Decisions on capital allocation, strategic partnerships, and executive compensation are directly influenced by the interests of its diverse shareholder base. The Xencor company's governance structure is designed to ensure accountability and alignment with shareholder value.

The voting structure for Xencor's common stock generally follows a one-share-one-vote system, common among publicly traded companies. This ensures that voting power directly reflects share ownership. There is no public information indicating dual-class shares or arrangements that would grant outsized control to particular individuals or entities beyond their equity stake. For more details on how the company operates, including its revenue streams, check out Revenue Streams & Business Model of Xencor.

Key Takeaways on Xencor's Board and Voting

The Board of Directors at Xencor plays a critical role in the company's governance, with a mix of independent directors and executives. The voting structure is typically one-share-one-vote, ensuring that voting power aligns with share ownership.

• The board includes the CEO and other experienced professionals.
• The voting structure is straightforward, with no special arrangements.
• Institutional investors have a significant influence on board decisions.
• The board oversees capital allocation and strategic partnerships.

Xencor Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, the ownership profile of the Xencor company has been shaped by various factors. Reviewing SEC filings provides insights into any share buybacks or secondary offerings that would alter the outstanding shares and ownership percentages. The company's strategic collaborations, such as the partnership with Astellas Pharma, could influence its financial standing and attractiveness to Xencor investors.

Leadership stability also plays a role, with key Xencor executives like Bassil Dahiyat providing continuity. Industry trends, like increased institutional ownership, are evident in the biopharmaceutical sector, reflecting its growth potential. The rise of activist investors, although not a major factor for Xencor recently, is a general trend that could impact governance and strategy. Clinical development programs and potential drug approvals could also draw in more investors, potentially changing the ownership base. For more information, you can explore the Competitors Landscape of Xencor.

Xencor ownership structure involves a mix of institutional investors, insiders, and potentially retail investors. The company's financials and stock performance are key in attracting and retaining investors. The board of directors and their holdings are also important aspects of the Xencor company ownership structure.

Institutional Ownership

Institutional investors hold a significant portion of Xencor stock, reflecting confidence in the company's long-term prospects. This includes major investment firms and mutual funds. Their ownership percentages are detailed in public filings.

Insider Ownership

Xencor executives and board members also hold shares, aligning their interests with those of other shareholders. Insider ownership levels provide insights into the leadership's commitment to the company's success. These details are disclosed in SEC filings.

Major Shareholders

Identifying Xencor major shareholders helps understand the company's ownership concentration. These shareholders often have a significant influence on the company's strategic decisions. Their holdings are regularly updated in public filings.

Ownership Percentage Breakdown

The Xencor ownership percentage breakdown shows the distribution of shares among different types of investors. This includes institutional, insider, and retail investors. The details are available in the company's annual reports and other SEC filings.

Xencor Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs